微泡
免疫系统
类风湿性关节炎
小RNA
医学
免疫学
关节炎
外体
滑液
自身免疫性疾病
癌症研究
成纤维细胞
抗体
体外
生物
病理
骨关节炎
基因
生物化学
替代医学
作者
Long‐Fei Wu,Qin Zhang,Xingbo Mo,Jun Lin,Yanglin Wu,Xin Lü,Pei He,Jian Wu,Yufan Guo,Mingjun Wang,Wenyan Ren,Hong‐Wen Deng,Shu‐Feng Lei,Fei‐Yan Deng
标识
DOI:10.1038/s12276-022-00751-x
摘要
Abstract Rheumatoid arthritis (RA) is an autoimmune disease characterized by infiltration of immune cells in the synovium. However, the crosstalk of immune cells and synovial fibroblasts is still largely unknown. Here, global miRNA screening in plasma exosomes was carried out with a custom microarray (RA patients vs. healthy controls = 9:9). A total of 14 exosomal miRNAs were abnormally expressed in the RA patients. Then, downregulated expression of exosomal miR-204-5p was confirmed in both the replication (RA patients vs. healthy controls = 30:30) and validation groups (RA patients vs. healthy controls = 56:60). Similar to the findings obtained in humans, a decreased abundance of exosomal miR-204-5p was observed in mice with collagen-induced arthritis (CIA). Furthermore, Spearman correlation analysis indicated that plasma exosomal miR-204-5p expression was inversely correlated with disease parameters of RA patients, such as rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein. In vitro, our data showed that human T lymphocytes released exosomes containing large amounts of miR-204-5p, which can be transferred into synovial fibroblasts, inhibiting cell proliferation. Overexpression of miR-204-5p in synovial fibroblasts suppressed synovial fibroblast activation by targeting genes related to cell proliferation and invasion. In vivo assays found that administration of lentiviruses expressing miR-204-5p markedly alleviated the disease progression of the mice with CIA. Collectively, this study identified a novel RA-associated plasma exosomal miRNA-204-5p that mediates the communication between immune cells and synovial fibroblasts and can be used as a potential biomarker for RA diagnosis and treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI